Harnessing Maturing Oligonucleotide Technologies to Unlock Undruggable CNS Targets with Enhanced RNA Chemistry & Innovative Delivery
Oligonucleotide R&D is accelerating, driven by advances in brain shuttle technologies, RNA chemistry, and growing clinical validation from leaders such as Alnylam Pharmaceuticals, Stoke Therapeutics, and Ionis Pharmaceuticals. At the same time, major investments, including Novartis into Arrowhead Pharmaceuticals, Biogen into City Therapeutics, and Roche into Manifold Bio, underscore CNS as a key frontier for these technologies, unlocking previously undruggable targets.
Building on last year’s momentum, the 6th Annual Oligonucleotides for CNS Summit will bring together 160+ experts across CNS biology, oligo chemistry, RNA science, and DMPK. Attendees will explore the latest innovations advancing nucleic acid therapies for neurodegenerative, neuromuscular, rare, epileptic, and neurodevelopmental disorders.
This summit uniquely connects stakeholders at the intersection of oligonucleotides and CNS. Join leaders from Eli Lilly, Dyne Therapeutics, Creyon Bio, and more for three days of collaboration to accelerate RNA-targeted CNS therapies.
Attending Companies Include